Markwin Maring

Markwin Maring has over 35 years of experience as an entrepreneur and investor in private equity and public companies, with a focus on life sciences, medtech, financial services, and software development. After a career in marketing and communications, Maring co- founded the MeesPierson Informal Opportunity Fund in 2000 in partnership with MeesPierson Private Bank, followed by the Concordia Fund N.V. in 2007. These funds were invested in various companies across different sectors, including the medical imaging company Oldelft Benelux, which was part of Delft Instruments N.V. Since 2010, Markwin has built his own investment portfolio, including the Dutch company Coretag IP, which discovered and patented a unique proprietary necrosis targeting technology. In 2019, Markwin moved Coretag’s activities to Switzerland, making Coretag part of Basel’s excellent biotech ecosystem. Besides Chairman of the Board, Markwin Maring currently has the role of CFO with additional major contribution in efforts launching Coretag, Inc. as a public USA company.